BridgeBio spins out oncology company as it focuses on heart drug

BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an anticipated launch of its pivotal heart drug.

The subsidiary, a company called TheRAS that is developing treatments for cancers with mutations in the KRAS gene, will become BridgeBio Oncology Therapeutics. The spinout is backed by $200 million in private financing led by Cormorant Asset Management and Omega Funds, with participation from other firms including Deerfield Management and Google Ventures, BridgeBio said Thursday.

BridgeBio will still have an ownership stake in the new company, but it wouldn’t disclose how large. The spinout is advancing three drug candidates, one that’s being tested in a Phase 1 trial and two others that are preclinical.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In